Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Antimicrobial Properties of Copper-Doped ZnO Coatings under Darkness and White Light Illumination.

Hassan IA, Sathasivam S, Nair SP, Carmalt CJ.

ACS Omega. 2017 Aug 31;2(8):4556-4562. doi: 10.1021/acsomega.7b00759. Epub 2017 Aug 16.

2.

Transforming a Simple Commercial Glue into Highly Robust Superhydrophobic Surfaces via Aerosol-Assisted Chemical Vapor Deposition.

Zhuang A, Liao R, Lu Y, Dixon SC, Jiamprasertboon A, Chen F, Sathasivam S, Parkin IP, Carmalt CJ.

ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42327-42335. doi: 10.1021/acsami.7b13182. Epub 2017 Nov 17.

PMID:
29116744
3.

Chemical Vapor Deposition Synthesis and Optical Properties of Nb2O5 Thin Films with Hybrid Functional Theoretical Insight into the Band Structure and Band Gaps.

Sathasivam S, Williamson BAD, Althabaiti SA, Obaid AY, Basahel SN, Mokhtar M, Scanlon DO, Carmalt CJ, Parkin IP.

ACS Appl Mater Interfaces. 2017 May 31;9(21):18031-18038. doi: 10.1021/acsami.7b00907. Epub 2017 May 19.

PMID:
28492079
4.

A single-source precursor approach to solution processed indium arsenide thin films.

Marchand P, Sathasivam S, Williamson BA, Pugh D, Bawaked SM, Basahel SN, Obaid AY, Scanlon DO, Parkin IP, Carmalt CJ.

J Mater Chem C Mater. 2016 Jul 28;4(28):6761-6768. Epub 2016 Jun 23.

5.

Tungsten Doped TiO2 with Enhanced Photocatalytic and Optoelectrical Properties via Aerosol Assisted Chemical Vapor Deposition.

Sathasivam S, Bhachu DS, Lu Y, Chadwick N, Althabaiti SA, Alyoubi AO, Basahel SN, Carmalt CJ, Parkin IP.

Sci Rep. 2015 Jun 4;5:10952. doi: 10.1038/srep10952.

6.

Repellent materials. Robust self-cleaning surfaces that function when exposed to either air or oil.

Lu Y, Sathasivam S, Song J, Crick CR, Carmalt CJ, Parkin IP.

Science. 2015 Mar 6;347(6226):1132-5. doi: 10.1126/science.aaa0946.

7.

Single-step co-deposition of nanostructured tungsten oxide supported gold nanoparticles using a gold-phosphine cluster complex as the gold precursor.

Molkenova A, Sarip R, Sathasivam S, Umek P, Vallejos S, Blackman C, Hogarth G, Sankar G.

Sci Technol Adv Mater. 2014 Dec 9;15(6):065004. eCollection 2014 Dec.

8.

Universal health coverage and the post-2015 agenda.

Touraine M, Gröhe H, Coffie RG, Sathasivam S, Juan M, Louardi el H, Seck AC.

Lancet. 2014 Sep 27;384(9949):1161-2. doi: 10.1016/S0140-6736(14)61419-7. Epub 2014 Sep 18. No abstract available.

PMID:
25242037
9.

PbO-modified TiO2 thin films: a route to visible light photocatalysts.

Bhachu DS, Sathasivam S, Carmalt CJ, Parkin IP.

Langmuir. 2014 Jan 21;30(2):624-30. doi: 10.1021/la4038777. Epub 2014 Jan 6.

PMID:
24354409
10.

Immunodeficiency, centromeric region instability and facial anomalies (ICF) syndrome diagnosed in an adult who is now a long-term survivor.

Sathasivam S, Selvakumaran A, Jones QC, Wathen CG.

BMJ Case Rep. 2013 Aug 5;2013. pii: bcr2013200170. doi: 10.1136/bcr-2013-200170.

11.

Design optimization of pin fin geometry using particle swarm optimization algorithm.

Hamadneh N, Khan WA, Sathasivam S, Ong HC.

PLoS One. 2013 May 31;8(5):e66080. doi: 10.1371/journal.pone.0066080. Print 2013.

12.

Patent foramen ovale and migraine: what is the relationship between the two?

Sathasivam S, Sathasivam S.

J Cardiol. 2013 Apr;61(4):256-9. doi: 10.1016/j.jjcc.2012.12.005. Epub 2013 Feb 26. Review.

13.

Statin induced myotoxicity.

Sathasivam S.

Eur J Intern Med. 2012 Jun;23(4):317-24. doi: 10.1016/j.ejim.2012.01.004. Epub 2012 Feb 4. Review.

PMID:
22560377
14.

Optimizing secondary prevention: Statin prescribing across East and West London in accordance with NICE guidelines.

Shakur R, Sathasivam S, Yu C, Cheung I, Selvakumaran A, Anandarajah C, Shakur A, Kaler M, McElligott G.

JRSM Short Rep. 2011 Jul;2(7):63. doi: 10.1258/shorts.2011.011027. Epub 2011 Jul 26.

15.

Current and emerging treatments for the management of myasthenia gravis.

Sathasivam S.

Ther Clin Risk Manag. 2011;7:313-23. doi: 10.2147/TCRM.S14015. Epub 2011 Jul 22.

16.

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

Young CA, Ellis C, Johnson J, Sathasivam S, Pih N.

Cochrane Database Syst Rev. 2011 May 11;(5):CD006981. doi: 10.1002/14651858.CD006981.pub2. Review.

PMID:
21563158
17.

Motor neurone disease: clinical features, diagnosis, diagnostic pitfalls and prognostic markers.

Sathasivam S.

Singapore Med J. 2010 May;51(5):367-72; quiz 373. Review.

18.

Managing patients with amyotrophic lateral sclerosis.

Sathasivam S.

Eur J Intern Med. 2009 Jul;20(4):355-8. doi: 10.1016/j.ejim.2008.09.002. Epub 2008 Oct 11. Review.

PMID:
19524172
19.

Immunosuppressant drugs for myasthenia gravis.

Hart IK, Sharshar T, Sathasivam S.

J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):5-6; discussion 6. doi: 10.1136/jnnp.2008.144980. Review.

PMID:
19091704
20.

Statin induced myopathy.

Sathasivam S, Lecky B.

BMJ. 2008 Nov 6;337:a2286. doi: 10.1136/bmj.a2286. Review. No abstract available.

PMID:
18988647

Supplemental Content

Loading ...
Support Center